Interim report January - March 2008

Interim report January - March 2008

Key events in the first quarter
• LinkMed and SLS Venture co-invest in ONCOlog Medical
• ALMI Företagspartner becomes a new financer in Biovator
• IMED licenses world-leading technology from Medarex
• Agneta Edberg appointed new Chief Operating Officer (COO) and Jonas
Graff-Lonnevig becomes new VP Financial Transactions with responsibility for
exits

Key events after the period end
• Anders Karlsson appointed new CEO in AbSorber AB
• AbSorber is granted a patent in the U.S. for its AB0 column 
• IMED's basic patent is granted patent protection in Europe
• Birgitta Gunneflo was elected new board member by the 2008 AGM

Financial information January- March 2008
• Results from investing activities amounted to SEK 0 million (0) 
• Other income amounted to SEK 1.1 million (1.2) 
• Net Income/loss after tax amounted to SEK -3.5 million (-2.2) 
• Earnings per share was SEK -0.40 (-0.25) 
• Shareholders' equity amounted to SEK 275.0 million compared to SEK 278.5
million at the year-end
• Shareholders' equity per share was SEK 31.38, compared to SEK 31.93 at the
year-end
• Equity/assets ratio was 98 percent, the same as at the year-end
• Liquid funds were SEK 112.1 million, compared to SEK 125.2 million at the
year-end.

CEO Ingemar Lagerlöf's comments on the first quarter 2008:
”With a stronger organization now in place, we have started exit preparations
for a few of our portfolio companies. Following ONCOlog Medical's successes last
year, SLS Venture is a new partner and the company is intensifying
commercialization of its products. The first quarter was intensive and I expect
a continued high tempo for the rest of 2008. ”


For additional information please contact:
Ingemar Lagerlöf, CEO, cell: +46 (0)70 873 2733 or email
ingemar.lagerlof@linkmed.se 
Okee Williams, Portfolio Manager, cell: +46 (0)70 600 5364 or email
okee.williams@linkmed.se


LinkMed develops life-science companies in collaboration with innovators. By
contributing entrepreneurship and capital, LinkMed has created a portfolio of
twelve companies, six in drug development and biotechnology and six in medical
technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm and
the company's largest partners are FastPartner, Koncentra Holding and the
founder Ingemar Lagerlöf. See www.linkmed.se for more information.